Clinical Trials Browser

Completed × OTHER × Carcinoma, Islet Cell × Clear all

Carcinoma, Islet Cell, Carcinoma, Neuroendocrine

NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT01525082 2024-02-06

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Phase 2 Completed

20 enrolled 15 charts

EndocrineGastrointestinal

Glucagonoma, Insulinoma, Pancreatic Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT02259725 2021-12-15

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Phase 2 Completed

3 enrolled 7 charts

Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT01465659 2021-08-05

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Phase 1/2 Completed

29 enrolled 16 charts

Carcinoma, Islet Cell

NCT00049023 2016-06-21

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Phase 1 Completed

27 enrolled

CNSEndocrineSarcoma

Familial ependymoma, Insulinoma, Adenoma, Islet Cell, Medulloblastoma, Neuroblastoma, Pheochromocytoma, Sarcoma, Gastrinoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Carcinoma, Islet Cell

NCT01155258 2016-06-13

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1 Completed

19 enrolled

BreastCNSDermatologicEndocrineGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Paraganglioma, Extra-Adrenal, Pheochromocytoma, Prostatic Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT00416767 2016-05-30

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Phase 2 Completed

20 enrolled

Endocrine

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00027638 2013-06-18

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 2 Completed

EndocrineThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Clinical Trials

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors